A RAND/UCLA-Modified VAS Study on Telemedicine, Telehealth, and Virtual Care in Daily Clinical Practice of Vascular Medicine.

Publication date: Mar 18, 2024

Background: Telemedicine is increasingly used in several fields of healthcare, including vascular medicine. This study aimed to investigate the views of experts and propose clinical practice recommendations on the possible applications of telemedicine in vascular medicine. Methods: A clinical guidance group proposed a set of 67 clinical practice recommendations based on the synthesis of current evidence and expert opinion. The Telemedicine Vascular Medicine Working Group included 32 experts from Europe evaluating the appropriateness of each clinical practice recommendation based on published RAND/UCLA methodology in two rounds. Results: In the first round, 60. 9% of clinical practice recommendations were rated as appropriate, 35. 9% as uncertain, and 3. 1% as inappropriate. The strongest agreement (a median value of 10) was reached on statements regarding the usefulness of telemedicine during the 2019 coronavirus disease (COVID-19) pandemic, its usefulness for geographical areas that are difficult to access, and the superiority of video calls compared to phone calls only. The lowest degree of agreement (a median value of 2) was reported on statements regarding the utility of telemedicine being limited to the COVID-19 pandemic and regarding the applicability of teleconsultation in the diagnosis and management of abdominal aortic aneurysm. In the second round, 11 statements were re-evaluated to reduce variability. Conclusions: This study highlights the levels of agreement and the points that raise concern on the use of telemedicine in vascular medicine. It emphasizes the need for further clarification on various issues, including infrastructure, logistics, and legislation.

Open Access PDF

Concepts Keywords
Coronavirus telehealth
Daily telemedicine
Europe vascular medicine
Medicine
Ucla

Semantics

Type Source Name
pathway KEGG Coronavirus disease
disease MESH COVID-19
disease MESH abdominal aortic aneurysm
drug DRUGBANK Coenzyme M
disease MESH Vascular Diseases
disease MESH Cancer
disease MESH Inflammation
disease MESH Diabetic Foot
disease MESH Cardiovascular Diseases
pathway REACTOME Hemostasis
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH chronic diseases
disease VO population
drug DRUGBANK Aspartame
disease VO effective
disease MESH peripheral arterial disease
drug DRUGBANK Indoleacetic acid
disease MESH morbidity
disease IDO history
disease MESH Venous Insufficiency
disease MESH Raynaud Phenomenon
disease MESH Ulcers
disease VO effectiveness
disease MESH thrombosis
disease MESH Buerger’s disease
disease MESH critical limb ischemia
disease MESH syndrome
disease MESH intermittent claudication
disease MESH venous ulcers
disease MESH varicose veins
disease MESH lymphedema
disease MESH ischemia
disease MESH deep vein thrombosis
disease MESH pulmonary embolism
disease VO efficiency
disease MESH emergency
disease IDO country
disease VO viability
drug DRUGBANK Trestolone
disease MESH aortic aneurysm
disease MESH uncertainty
drug DRUGBANK Huperzine B
disease VO Gap
drug DRUGBANK Spinosad
disease MESH heart failure
disease VO USA
disease VO vein
drug DRUGBANK Levamlodipine
drug DRUGBANK Dosulepin

Original Article

(Visited 1 times, 1 visits today)